Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 28, 2012

View Archived Issues

EE-TP shows promise for the treatment of MNGIE

New DNA supercoiling inhibitors for bacterial infections presented by Biota

Kalidex conducts phase I study of novel fluoroquinolone antibiotic

Teijin Pharma gains rights to investigational bronchial asthma drug

ASSURE trial of RVX-208 completes enrollment

Cannabis Science initiates European preclinical program for CS-TATI-1

Prozymex presents novel dipeptidyl peptidase 1 inhibitors

Chinese researchers synthesize new androgen receptor antagonists

Abbott launches Absorb bioresorbable vascular scaffold

Sanofi discloses several new agents for diabetes

Reckitt Benckiser to discontinue supply of Suboxone tablets in U.S.

Array BioPharma and Genentech report novel ERK inhibitors

Forest Laboratories submits NDA for levomilnacipran

Pharming completes phase III Ruconest study

FDA grants priority review status to sNDA for Amitiza

Bristol-Myers Squibb files application in Japan for Taxol for germ cell tumors

FDA acknowledges receipt of NDA resubmission for Eliquis

Pfizer and Acura Pharmaceuticals terminate license agreement

FDA accepts NDA for FF/VI for COPD

EMA recommends approval of ingenol mebutate for actinic keratosis

UCB's phase IIb study of olokizumab meets primary endpoint

Positive results reported from phase Ib trial of ACH-3102

BioMarin to start phase III program for PEG-PAL in 2013

Merck & Co. returns vernakalant rights

FDA approves Bayer's Stivarga for treatment of metastatic colorectal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...